ABNCoV2

ABNCoV2
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Intramuscular
Identifiers
CAS Number

ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.[2][3][4][5]

On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.[6]

References

  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ↑ "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". Bavarian Nordic. 8 March 2021. Retrieved 13 April 2021.
  3. ↑ Clinical trial number NCT04839146 for "Safety and Tolerability of ABNCoV2 (COUGH-1)" at ClinicalTrials.gov
  4. ↑ "Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021.
  5. ↑ Clinical trial number NCT05077267 for "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects" at ClinicalTrials.gov
  6. ↑ Svansø VL (9 August 2021). "Foreløbige resultater: Dansk vaccine virker i første forsøg med mennesker – og den virker godt". Berlingske.dk (in Danish). Retrieved 25 January 2023.


This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.